期刊
CANCER CELL
卷 28, 期 3, 页码 318-328出版社
CELL PRESS
DOI: 10.1016/j.ccell.2015.07.013
关键词
-
资金
- Korea Healthcare Technology R&D Project from Korea Health Industry Development Institute and Ministry for Health & Welfare Affairs, Korea [HI14C3418, HI13C2096]
- Korea Health Promotion Institute [HI14C3418980015, HI13C2096010015] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Tumor recurrence following treatment is the major cause of mortality for glioblastoma multiforme (GBM) patients. Thus, insights on the evolutionary process at recurrence are critical for improved patient care. Here, we describe our genomic analyses of the initial and recurrent tumor specimens from each of 38 GBM patients. A substantial divergence in the landscape of driver alterations was associated with distant appearance of a recurrent tumor from the initial tumor, suggesting that the genomic profile of the initial tumor can mislead targeted therapies for the distally recurred tumor. In addition, in contrast to IDH1-mutated gliomas, IDH1-wild-type primary GBMs rarely developed hypermutation following temozolomide (TMZ) treatment, indicating low risk for TMZ-induced hypermutation for these tumors under the standard regimen.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据